Search
Check Out Our Sponsors
Latest topics
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
Page 1 of 1
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
Dermatol Res Pract. 2014;2014:734249. Epub 2014 Mar 2.
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
Chanprapaph K, Vachiramon V, Rattanakaemakorn P.
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cutaneous adverse events are common due to the interference of epidermal growth factor receptor (EGFR) signaling in the skin. Cutaneous toxicities lead to poor compliance, drug cessation, and psychosocial discomfort. This paper summarizes the current knowledge concerning the presentation and management of skin toxicity from EGFRI. The common dermatologic adverse events are papulopustules and xerosis. Less common findings are paronychia, regulatory abnormalities of hair growth, maculopapular rash, mucositis, and postinflammatory hyperpigmentation. Radiation enhances EGFRI rash due to synergistic toxicity. There is a positive correlation between the occurrence and severity of cutaneous adverse effects and tumor response. To date, prophylactic systemic tetracycline and tetracycline class antibiotics have proven to be the most effective treatment regime.
Full study:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/
Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management.
Chanprapaph K, Vachiramon V, Rattanakaemakorn P.
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cutaneous adverse events are common due to the interference of epidermal growth factor receptor (EGFR) signaling in the skin. Cutaneous toxicities lead to poor compliance, drug cessation, and psychosocial discomfort. This paper summarizes the current knowledge concerning the presentation and management of skin toxicity from EGFRI. The common dermatologic adverse events are papulopustules and xerosis. Less common findings are paronychia, regulatory abnormalities of hair growth, maculopapular rash, mucositis, and postinflammatory hyperpigmentation. Radiation enhances EGFRI rash due to synergistic toxicity. There is a positive correlation between the occurrence and severity of cutaneous adverse effects and tumor response. To date, prophylactic systemic tetracycline and tetracycline class antibiotics have proven to be the most effective treatment regime.
Full study:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958662/
_________________
My regimen
http://www.immortalhair.org/mpb-regimen
Now available for consultation (hair and/or health)
http://www.immortalhair.org/health-consultation
Similar topics
» Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor.
» Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
» Hair growth and epidermal growth factor receptor (EGFR)
» Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
» Cutaneous side effects of EGFR inhibitors - appearance and management.
» Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients.
» Hair growth and epidermal growth factor receptor (EGFR)
» Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
» Cutaneous side effects of EGFR inhibitors - appearance and management.
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Fri May 17, 2024 7:01 am by Atlas
» zombie cells
Sat May 11, 2024 6:54 am by CausticSymmetry
» Sandalore - could it be a game changer?
Wed May 08, 2024 9:45 pm by MikeGore
» *The first scientific evidence in 2021 that viruses do not exist*
Tue May 07, 2024 4:18 am by CausticSymmetry
» China is at it again
Tue May 07, 2024 4:07 am by CausticSymmetry
» Ways to increase adult stem cells
Mon May 06, 2024 5:40 pm by el_llama
» pentadecanoic acid
Sun May 05, 2024 10:56 am by CausticSymmetry
» Exosome Theory and Herpes
Fri May 03, 2024 3:25 am by CausticSymmetry
» Road to recovery - my own log of everything I'm currently trying for HL
Tue Apr 30, 2024 1:55 pm by JtheDreamer